[EGFR mutation analysis in non-small-cell lung cancer : Experience from routine diagnostics].

摘要: BACKGROUND Some patients with non-small cell lung cancer (NSCLC) respond well to therapy tyrosine kinase inhibitors (TKI). Somatic mutation of the epidermal growth factor receptor (EGFR) gene is an important predictive marker for TKI response. PATIENTS AND METHODS We performed EGFR analysis in 307 NSCLC (exon 18-21). The data were analyzed associations clinical-pathological parameters. RESULTS Relevant mutations found 25/307 (8.1%; 178 biopsies and 129 cytologies). Most exon 19 (50%) followed by L858R point 21 (12.5%). significantly more common women than men (16.8% vs. 2.7%; p<0.001) adenocarcinoma other carcinoma subtypes (11.4% 3.8%; p=0.017). was associated TTF-1 positivity (p<0.041). Almost all (96%) mutated positive. CONCLUSION In Central Europe, prevalence relevant <10% NSCLC. are positive adenocarcinomas. Mutation can be both from cytologies.